# Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

> **NCT05642078** · PHASE3 · COMPLETED · sponsor: **Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.** · enrollment: 2550 (actual)

## Conditions studied

- Prevention of Influenza

## Interventions

- **BIOLOGICAL:** Investigational Vaccine(0.25ml/vial)
- **BIOLOGICAL:** Investigational Vaccine(0.5ml/vial)
- **BIOLOGICAL:** Active compared Vaccine

## Key facts

- **NCT ID:** NCT05642078
- **Lead sponsor:** Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-18
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-01-05
- **Target enrollment:** 2550 (ACTUAL)
- **Last updated:** 2024-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642078, "Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05642078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*